A CITF-funded study, published in preprint and not yet peer-reviewed, found that vaccination induced robust SARS-CoV-2-specific T-cells responses against Omicron variant BA.4/5, in solid organ transplant recipients (SOTRs).
Studies showed that in most immune-compromised individuals, booster doses were necessary and safe to boost much needed antibody and cell-mediated immunity levels, as their waning seems to occur faster.
A CITF-funded study, published in Transplantation and Cellular Therapy, found that a fourth dose of the COVID-19 vaccine is highly immunogenic (induces a good immune response) and safe in people who have a received an allogeneic Hematopoietic Stem Cell Transplant (HSCT).
A CITF-funded study, published in AIDS, found that vaccine-induced SARS-CoV-2 neutralization capacity was similar between people living with HIV (PLWH) and HIV-negative people without past COVID-19 infection.
A CITF-funded study, published in Canadian Journal of Kidney Health and Disease, found that COVID-19 vaccines were highly effective in preventing infection and severe outcomes among patients on maintenance dialysis in both British Columbia and Ontario.
A CITF-funded study, published in the International Journal of Infectious Diseases, found that people living with HIV (PLWH) had more than two times the risk of being hospitalized with COVID-19 as did HIV-negative individuals.
A CITF-funded study, published in preprint and not yet peer-reviewed, found older people living with HIV require at least three doses of COVID-19 vaccines to maximize immune responses against SARS-CoV-2.
A CITF-funded study, published in The Journal of Immunology, demonstrates that third and fourth doses of vaccine sustain and broaden immune responses to SARS-CoV-2 in adults with immune-mediated inflammatory diseases (IMIDs).
A CITF-funded study, published in The American Journal of Gastroenterology, found that SARS-CoV-2 vaccines are safe for those with inflammatory bowel disease (IBD). Injection site reactions were the most common adverse event, most common after earlier doses, but when following a 4th dose, they were significantly associated with increased antibody levels.
A CITF-funded study, published in Clinical Infectious Diseases, reported that a fourth vaccine dose significantly increases BA.4/5-specific neutralizing antibodies, as well as CD4+ T cell responses in solid organ transplant recipients (SOTR).